Feed aggregator

Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros

World Pharma News - Fri, 12/02/2022 - 11:00
Bayer supports rebuilding of the Ukrainian healthcare system with a donation of 1.3 million euros to the UNITED24 fundraising platform. UNITED24 was launched in May 2022 by the President of Ukraine, Volodymyr Zelensky, as the primary platform for charitable donations to reconstruct Ukraine.

GSK Notches Phase III Win for Jemperli in Endometrial Cancer

Biospace news - Fri, 12/02/2022 - 02:00
​​​​​​​GSK intends to file for approval of Jemperli in endometrial cancer after the checkpoint inhibitor met its primary endpoint in the Phase III RUBY trial.

FDA Clears First IND for a Multiplex-Base Edited Investigational Therapy

Biospace news - Fri, 12/02/2022 - 02:00
The FDA has lifted its clinical hold on Beam Therapeutics’ BEAM-201 and cleared the way for an Investigational New Drug Application, the company announced Friday.

Athira’s Alzheimer’s Therapy Climbs Ranks in a Competitive Space

Biospace news - Fri, 12/02/2022 - 02:00
Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show signs of being able to improve cognition and function in patients.

Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis

Biospace news - Fri, 12/02/2022 - 02:00
Amid rampant buyout speculation, Mirati Therapeutics reported that it will continue its final analysis of the Phase III SAPPHIRE trial following an interim survival analysis.

FDA Greenlights Rigel's Rezlidhia in IDH1-Mutation AML

Biospace news - Fri, 12/02/2022 - 02:00
The FDA has approved Rigel's Rezlidhia for the treatment of adults with relapsed or refractory AML with a susceptible isocitrate dehydrogenase-1 mutation.

10 Massachusetts Biopharma Companies Hiring Now

Biospace news - Fri, 12/02/2022 - 02:00
Home to many of the world's leading life science companies, the Genetown hotbed is a hub of activity. To help you in your job search, here are 10 Massachusetts biopharma companies hiring now.

Nanotech strategy shows promise for treating autoimmune disease

World Pharma News - Thu, 12/01/2022 - 11:00
Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases.

The scientists, who reported their results on November 23, 2022, in the journal ACS Nano, engineered cell-like "nanoparticles" that target only the immune cells driving an autoimmune reaction, leaving the rest of the immune system intact and healthy.

Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab

World Pharma News - Wed, 11/30/2022 - 11:00
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain,

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

World Pharma News - Tue, 11/29/2022 - 11:00
AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

The first potent COQ8 inhibitor targets ubiquinone biosynthesis

World Pharma News - Mon, 11/28/2022 - 13:00
Inhibition of the COQ8 protein could be beneficial in the treatment of diseases such as cancer. COQ8 is needed for the biosynthesis of coenzyme Q, also known as ubiquinone. A new collaborative study from the University of Eastern Finland, Washington University in St. Louis, University of Wisconsin-Madison, University of North Carolina at Chapel Hill and the Promega Corporation discloses the discovery and application of a new chemical probe to selectively inhibit human COQ8A in cells.

14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies

World Pharma News - Mon, 11/28/2022 - 11:00
8 - 9 February 2023, London, United Kingdom.
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

AI tailors artificial DNA for future drug development

World Pharma News - Fri, 11/25/2022 - 13:00
With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells' protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs than today.

Remdesivir reduces COVID-19 mortality in a real-world setting

World Pharma News - Fri, 11/25/2022 - 11:00
The COVID-19 pandemic has led to an explosion of clinical research resulting in the development of a variety of vaccines and treatments, although the efficacy of some remains controversial. Now, researchers from Japan report that remdesivir, a drug whose effectiveness has been debated, appears to make a big difference in Japanese patients with COVID-19 who received corticosteroids in the ICU.

Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster

World Pharma News - Thu, 11/24/2022 - 11:00
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

Pocket feature shared by deadly coronaviruses could lead to pan-coronavirus antiviral treatment

World Pharma News - Wed, 11/23/2022 - 11:00
Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now. Researchers of the University of Bristol-led study, published in Science Advances today, say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses - from the 2002 SARS-CoV outbreak to Omicron, the current variant of SARS-CoV-2, as well as dangerous variants that may emerge in future.

FDA Approves CSL-uniQure's Hemophilia B Gene Therapy, the Most Expensive Medicine in the World

Biospace news - Wed, 11/23/2022 - 02:00
The FDA approved CSL Behring and uniQure’s Hemgenix, a one-time gene therapy developed for adults with Hemophilia B,the companies announced Tuesday afternoon.

FDA Grants Priority Review to Takeda's Dengue Vaccine

Biospace news - Wed, 11/23/2022 - 02:00
The FDA granted priority review to Takeda’s Biologics License Application for TAK-003, a dengue vaccine candidate. The vaccine to date is only approved for use in Indonesia.

Arvinas’ Experimental Breast Cancer Drug Fails to Impress Analysts

Biospace news - Wed, 11/23/2022 - 02:00
Late Monday, Arvinas Inc. was forced to divulge the contents of its upcoming breast cancer data presentation, slated for the 2022 San Antonio Breast Cancer Symposium (“SABCS”).